TLR7 and neoplasm: Rodell and colleagues employed β-CD nanoparticles to deliver R848 (a TLR7/8 agonist) in multiple mouse tumor models, reprogramming the tumor immune microenvironment toward an M1 phenotype, controlling tumor growth, preventing rechallenge, and—when combined with anti-PD-1 therapy—improving immunotherapy response rates [191].